We describethe use of "high-performance" liquid chromatography to measure chloramphenicolinas little as 25 L of serum. Serum istreated to precipitate proteinswith acetonitrile containing p-nitroacetanilide as an internal standard.Chloramphenicol is eluted witha mobile phase of methanol inpH 7.0phosphate buffer (35/65 by vol). The drug ismeasured at 278 nm and simultaneously monitored at 254 nm; interfering substances are detected by examiningthe 278 nm/254 nm absorbance ratios. This method is sensitive to less than 0.5 mg/L and the standard curve is linear to at least 50 mg/L. Inter-day precision ranged between 3-6%. We encountered no interferencefrom endogenous compounds or from otherdrugs we tested.
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Chloramphenicol is a potent antibiotic with broad-spectrum antimicrobial activity (1) . Its effectiveness in treating Hemophilus influenzae meningitis and other diseases caused by bacteria resistant to II-lactam antibiotics has led to its increased use (2). Despite its therapeutic importance, it must be used cautiously because of potentially lethal side effects: aplastic anemia and the "gray-baby syndrome" as well as reversible bone-marrow suppression (1,3) . The latter two effects are directly related to the serum concentration of chloramphenicol. Because of its relatively low therapeutic index and poor correlation between dose and concentration in serum, measurement of serum chloramphenicol during therapy is essential. Most susceptible Gram-negative bacteria are inhibited by serum concentrations between 5 and 15 mg/L (4). As the concentration in serum increases above the therapeutic Department of Laboratory Medicine, University of Washington, Harborview Medical Center, Seattle, WA 98104. range, the frequency and severity of toxic side effects increase progressively.
Numerous methods have been developed for measuring chloramphenicol in serum: colorimetric (5), microbiological (6), and gas-chromatographic (7). The routine clinical utility of each of these methods is limited by one or more of the following: lack of sensitivity or specificity, lengthy or complex analysis, poor precision, or requirement for a large serum sample. Recent modifications of a radioenzymatic assay for chloramphenicol (8) have obviated these problems, but this assay still may not be practical for many clinical laboratories because of the lack of a commercial source of the acetyltransferase enzyme and the need for liquid scintillation counting equipment.
We present here a reversed-phase "high-performance" chromatographic method that is simple, rapid, accurate, precise, and for which less than 25 tL of serum is required. Sample preparation consists of precipitating proteins with acetonitrile containing the internal standard p-nitroacetanilide. Each analysis requires less than 15 mm. The method is sensitive and will detect chloramphenicol in concentrations as low as 0.5 mg/L. Our method uses the absorbance ratio technique (9, 10) to check for potential interference by monitoring simultaneously the absorbance at 278 nm and 254 nm.
Recently several groups have published methods for determination of chioramphenicol by high-performance liquid chromatography (11-13). The procedure of Nilssen-Ehle et al. (11) does not use an internal standard for quantitation, an omission that could result in poor precision if introduced into the routine clinical chemistry laboratory; the two other procedures (12, 13) require a more lengthy sample preparation involving organic-solvent extraction. In addition, in none of these procedures are absorbance ratios used to check for interfering substances.
Materials and Methods

Apparatus
We used a Model 204 high-performance liquid chromato- graph; the flow cell of the Model 440 absorbance detector (254 nm) in this system was connected in series to the Model 450 variable-wavelength detector (278 nm). The reversed-phase column, p-Bondapack C18, 30 cm X 4 mm, was maintained at room temperature (all of the preceding components were obtained from Waters Associates, Inc., Milford, MA 07157). A Whatman guard column filled with Co: Pell ODS (Alltech Associates, Inc., Arlington Heights, IL 94710) was connected to the inlet end of the column. The absorbance detectors were connected to a dual-pen recorder (Omniscribe, B-5000; Houston Instruments, Austin, TX 78742); chart speed was set at 0.5 cm/mm.
Samples were prepared in 500-pL polypropylene centrifuge tubes (Brinkmann Instruments, Inc., Westbury, NY 11590) and were centrifuged in a small high-speed centrifuge (Model 59; Fisher Scientific Co., Pittsburgh, PA 15219).
Reagents and Standards
Methanol and acetonitrile were glass distilled and were of ultraviolet grade (Burdick and Jackson Laboratories, Inc., Muskegon, MI 49442).
The 
Results and Discussion
Chromatograms from our assay are presented in Figure  1 .
The chromatogram of the supernate from blank serum treated with acetonitrile (no internal standard present) is shown in Figure 1A . The chromatogram in Figure lB shows the supernate from serum supplemented with 23.5 pg of chloramphenicol per milliliter and treated according to the procedure.
Chloramphenicol and the internal standard are eluted from the column in about 7 and 10 mm, respectively. The chloramphenicol concentration is determined from a standard curve established by plotting the peak-height ratio (height of chloramphenicol peak/height of internal standard peak) vs. chloramphenicol concentration.
The peak-height ratios were linearly related to concentration up to 50 mg/L. This method is sensitive enough to measure serum chloramphenicol concentrations as low as 0.5 mg/L.
The accuracy of the assay was established by determining absolute and relative analytical recoveries (Table 1) (Figure 2) . To assess the absolute recovery, we added chloramphenicol to drug-free serum to give the concentrations shown in Table 1A . These sera were analyzed by our procedure except that the acetonitrile used to precipitate protein did not contain the internal standard. Carefully measured aliquots of the supernate were then injected, and the heights of the resulting chioramphenicol peaks were measured. Absolute recovery was determined by comparing their peak heights to those obtained by direct injection of a comparable amount pure chloramphenicol standard. Table 1A indicates that absolute recoveries at low and high therapeutic concentrations averaged 104 and 102%, respectively. The relative recoveries (Table 1B) , also calculated for these concentrations, averaged 102 and 97%, respectively.
Accuracy was further evaluated by comparing results from our method with those of a microbiological assay (14). Figure  2 shows that, in general, results by the two methods correlate well.
We evaluated the precision of the assay by repeated analysis of serum that had been supplemented with chloramphenicol (Table 2) . Intra-day precision was 2.0% at the low therapeutic concentration and 0.6% at a high concentration, and interday precision was 5.6 and 2.9%, respectively.
To assess the specificity of our methods, we tested 24 drugs for possible interference (Table 3) ; none interfered with chloramphenicol or the internal standard, nor did we see any interference from endogenous serum constituents (including hemolyzed, icteric, and lipemic sera).
The specificity of our assay is also continually checked by using simultaneous dual-wavelength monitoring and applying the absorbance ratio method (9, 10). In this procedure the ratio between the peak heights of chloramphenicol at 278 nm (0.01 A full-scale) and 254 nm (0.005 A full-scale) is calculated for each sample. A similar ratio is obtained for the internal standard. The mean and standard deviation from 22 specimens were calculated for these ratios (Table 4) . When the ratio for either chioramphenicol or the internal standard exceeds the ± 3 SD range, the presence of an interfering substance is suggested, even when the peaks are symmetrical. Such samples must be interpreted with caution and should, preferably, be checked by an alternative procedure. (Two of 15 clinical specimens analyzed showed interference by this criterion.) Thus dual-wavelength monitoring provides an ongoing confirmation of peak integrity.
